Outcome of Board Meeting attached.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sunshield Chemicals' Board approved unaudited financial results for Q3 FY26 (quarter ended Dec 31, 2025) and the nine-month period, with auditors CNK & Associates LLP issuing an unmodified (clean) review report. Revenue from operations for Q3 stood at Rs. 9,496 lakhs versus Rs. 8,461 lakhs in Q3 FY25, while 9M FY26 revenue surged to Rs. 33,124 lakhs from Rs. 25,548 lakhs in 9M FY25 — a ~30% jump. Profit after tax for Q3 nearly tripled to Rs. 489 lakhs (vs Rs. 163 lakhs), and 9M PAT more than doubled to Rs. 1,894 lakhs (vs Rs. 883 lakhs), lifting 9M EPS to Rs. 24.61 from Rs. 11.85. The company also completed a Rights Issue in October 2025, raising Rs. 12,990.40 lakhs (allotment of 14.41 lakh shares at Rs. 901 each), with proceeds fully utilised for debt repayment and general corporate purposes by Dec 31, 2025.
Strong revenue and profit growth, a clean auditor opinion, and successful debt reduction via the Rights Issue are positive for shareholders. The sequential drop in Q3 revenue (from Rs. 12,240 lakhs in Q2) is worth watching, though the overall 9M trajectory remains robust.